Concert Pharmaceuticals Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Roth Boosts PT on Concert Pharma (CNCE) to $22 Following; Deuterium Platform, Partnerships Will Bolster Gains
May 8, 2015 3:08 PM EDTRoth Capital affirms Concert Pharmaceuticals, Inc. (CNCE) at Buy and moves its price target from $19 up to $22 following Q1 results and corporate update issued by the company ahead of the opening bell Friday.
Analyst Joseph Pantginis noted that CNCE reported Q1 loss of $0.48 per share, versus the firm's loss estimate of $0.28 per share.
Pantginis commented, While the stock... More
Concert Pharma (CNCE) Misses Q1 EPS by 4c
May 8, 2015 8:56 AM EDTConcert Pharma (NASDAQ: CNCE) reported Q1 EPS of ($0.48), $0.04 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $2.7 million.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More